Treatment of Metastatic Triple-Negative Breast Cancer
The Pharma Data
MARCH 25, 2021
The validation of our EU marketing application is an important step toward addressing the significant unmet medical need for people with metastatic triple-negative breast cancer.”. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Gilead Sciences, Inc.
Let's personalize your content